Patents by Inventor Charles N. Serhan

Charles N. Serhan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipoxin analogs and method for the treatment of periodontal disease
    Publication number: 20040019110
    Abstract: This invention provides new lipoxin analogs, compositions containing these analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation,including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the compositions containing lipoxin analogs, COX-2 inhibitors, or both.
    Type: Application
    Filed: September 20, 2002
    Publication date: January 29, 2004
    Inventors: Thomas E. Van Dyke, Nicos A. Petasis, Charles N. Serhan
  • Aspirin-triggered lipid mediators
    Patent number: 6670396
    Abstract: Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: December 30, 2003
    Assignee: Brigham and Women's Hospital
    Inventors: Charles N. Serhan, Clary B. Clish
  • Prevention of neutrophil recruitment
    Patent number: 6659282
    Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: December 9, 2003
    Assignee: Brigham and Women's Hospital
    Inventor: Charles N. Serhan
  • Lipoxin compounds and their use in treating cell proliferative disorders
    Patent number: 6653493
    Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: November 25, 2003
    Assignee: The Brigham and Women's Hospital
    Inventor: Charles N. Serhan
  • Lipoxin compounds and their use in treating cell proliferative disorders
    Patent number: 6635776
    Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: October 21, 2003
    Assignee: The Brigham and Women's Hospital
    Inventor: Charles N. Serhan
  • Novel approach to anti-microbial host defense with molecular shields with lipoxin compounds
    Publication number: 20030195248
    Abstract: Methods to cause tissue, such as mucosal cells, to express increased amounts of bactericidal permeability increasing protein (BPI) are described. The BPI inducing agents include, for example, lipoxin compounds.
    Type: Application
    Filed: December 18, 2002
    Publication date: October 16, 2003
    Inventors: Charles N. Serhan, Sean P. Colgan
  • Novel approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
    Publication number: 20030191184
    Abstract: Methods to cause tissue, such as mucosal cells, to express increased amounts of bactericidal permeability increasing protein (BPI) are described. Various BPI inducing agents include icosapentanoic acid (EPA) analogs and docosahexaenoic acid (DHA) analogs.
    Type: Application
    Filed: December 18, 2002
    Publication date: October 9, 2003
    Inventors: Charles N. Serhan, Sean P. Colgan
  • Prevention of neutrophil recruitment
    Publication number: 20030191332
    Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
    Type: Application
    Filed: February 13, 2003
    Publication date: October 9, 2003
    Inventor: Charles N. Serhan
  • Lipoxin analogs as novel inhibitors of angiogenesis
    Patent number: 6627658
    Abstract: The present invention is directed to methods for the prevention or inhibition of angiogenesis. The method is accomplished by the administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, LXA4, 15-epi-LXA4 or 15-R/S-methyl, LXA4 and pharmaceutically acceptable salts, esters, amides, carboxylic acids, or prodrugs thereof, to a subject in need thereof. As a consequence of the action of the therapeutic agent, angiogenesis is prevented or inhibited in the subject.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: September 30, 2003
    Assignee: The Brigham and Women's Hospital
    Inventors: Charles N. Serhan, Iolanda M. Fierro
  • Lipoxin compounds and their use in treating cell proliferative disorders
    Patent number: 6620919
    Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: September 16, 2003
    Assignee: The Brigham and Women's Hospital
    Inventor: Charles N. Serhan
  • Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
    Publication number: 20030166716
    Abstract: The use of lipoxin analogs for the treatment or prevention of asthma and asthma related diseases is described. In particular, acetylenic lipoxin analogs are effective for the treatment and prevention of eosinophil recruitment involved with the inflammation processes associated with asthma, asthma like conditions, and lung injuries associated from airway inflammation or infection as brought about by leukocyte-mediated injury from within.
    Type: Application
    Filed: November 6, 2002
    Publication date: September 4, 2003
    Inventors: Charles N. Serhan, Bruce D. Levy
  • Lipoxin compounds and their use in treating cell proliferative disorders
    Publication number: 20030134901
    Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.
    Type: Application
    Filed: December 2, 2002
    Publication date: July 17, 2003
    Inventor: Charles N. Serhan
  • Lipoxin compounds and their use in treating cell proliferative disorders
    Patent number: 6569075
    Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: May 27, 2003
    Assignee: Brigham and Women's Hospital
    Inventor: Charles N. Serhan
  • PREVENTION OF NEUTROPHIL RECRUITMENT
    Publication number: 20030069435
    Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
    Type: Application
    Filed: June 20, 2002
    Publication date: April 10, 2003
    Inventor: Charles N. Serhan
  • Modulation of inflammation related to columnar epithelia
    Publication number: 20030060512
    Abstract: This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.
    Type: Application
    Filed: September 24, 2002
    Publication date: March 27, 2003
    Inventors: James L. Madara, Charles N. Serhan, Sean P. Colgan
  • Prevention of neutrophil recruitment
    Publication number: 20030055275
    Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
    Type: Application
    Filed: June 20, 2002
    Publication date: March 20, 2003
    Inventor: Charles N. Serhan
  • Lipoxin compounds and their use in treating cell proliferative disorders
    Publication number: 20030032827
    Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.
    Type: Application
    Filed: June 19, 2002
    Publication date: February 13, 2003
    Inventor: Charles N. Serhan
  • Lipoxin analogs as novel inhibitors of angiogenesis
    Publication number: 20020193431
    Abstract: The present invention is directed to methods for the prevention or inhibition of angiogenesis. The method is accomplished by the administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, LXA4, 15-epi-LXA4 or 15-R/S-methyl, LXA4 and pharmaceutically acceptable salts, esters, amides, carboxylic acids, or prodrugs thereof, to a subject in need thereof. As a consequence of the action of the therapeutic agent, angiogenesis is prevented or inhibited in the subject.
    Type: Application
    Filed: March 1, 2002
    Publication date: December 19, 2002
    Inventors: Charles N. Serhan, Iolanda M. Fierro
  • Inhibition of TNF-alpha-initiated neutrophil response
    Publication number: 20020143069
    Abstract: The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF&agr;)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA4 and ATL analogs each inhibited TNF&agr;-stimulated superoxide anion generation and IL-1&bgr; release by human PMN.
    Type: Application
    Filed: January 11, 2002
    Publication date: October 3, 2002
    Inventor: Charles N. Serhan
  • Modulation of inflammation related to columnar epithelia
    Patent number: 6458839
    Abstract: This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: October 1, 2002
    Assignee: The Brigham and Women's Hospital
    Inventors: James L. Madara, Charles N. Serhan, Sean P. Colgan